Niedbala M J, Picarella M S
Institute of Arthritis and Autoimmunity, Miles Research Center, Miles Inc, West Haven, CT. 06516.
Blood. 1992 Feb 1;79(3):678-87.
Tumor necrosis factor (TNF) has a profound capacity to alter the endothelial cell phenotype that includes morphologic and functional changes that may be central for proinflammatory processes. Recent observations have indicated that TNF can promote the synthesis and secretion of urokinase plasminogen activator (uPA) in low passage human endothelial cells that normally release little uPA. In this report we have confirmed and expanded upon these initial observations in human endothelial cells and describe the ability of gamma-interferon (gamma-IFN) to inhibit TNF-induced uPA synthesis and secretion in a dose-dependent manner (0.025 to 25 ng/mL). Analysis of cell-free conditioned medium derived from gamma-IFN-treated cultures by micro-enzyme-linked immunosorbent assay (ELISA) methodologies using uPA- and plasminogen activator inhibitor type 1 (PAI-1)-specific monoclonal antibodies (MoAbs) indicate that the decrease in uPA activity observed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) zymography is a direct result of a decrease in extracellular uPA antigen and is not a consequence of increased PAI-1 antigen. These findings are supported by Northern blot analyses that indicate that gamma-IFN treatment of endothelial cells resulted in a decreased steady state level of uPA messenger RNA (mRNA) with no measurable change in PAI-1 mRNA. This inhibitory response is specific for gamma-IFN because alpha-IFN fails to elicit a similar inhibitory response. In addition, TNF augmented extracellular proteolysis of radiolabeled subendothelial extracellular matrix (ECM) in a dose-dependent manner. The observed increase in ECM degradation mediated by TNF treatment of endothelial cells was dependent on the presence of plasminogen and could be inhibited by an anticatalytic uPA MoAb implying the requirement of proteolytically active uPA in this process. gamma-IFN (25 ng/mL) treatment of endothelial cells antagonized TNF-promoted degradation of radiolabeled ECM at a concentration that completely inhibited TNF-mediated uPA expression and activity. In addition, endothelial cells treated with TNF (18 hours) displayed the ability to invade ECM and reorganize individual cells into tube-like structures that were not evident in untreated control cultures when grown on Matrigel-coated culture dishes. gamma-IFN treatment of endothelial cells propagated on Matrigel was observed to inhibit TNF-mediated ECM invasion and tube formation at concentrations that were analogous to those required for the inhibition of uPA expression and activity. In summary, these observations suggest a novel homeostatic control mechanism for endothelial cell regulation of subendothelial ECM degradation promoted by TNF and inhibited by gamma-IFN.(ABSTRACT TRUNCATED AT 400 WORDS)
肿瘤坏死因子(TNF)具有显著改变内皮细胞表型的能力,这些改变包括形态学和功能变化,而这些变化可能是促炎过程的核心。最近的观察表明,TNF可促进低代次人内皮细胞中尿激酶型纤溶酶原激活剂(uPA)的合成与分泌,而这些细胞通常很少释放uPA。在本报告中,我们证实并扩展了在人内皮细胞中的这些初步观察结果,并描述了γ-干扰素(γ-IFN)以剂量依赖性方式(0.025至25 ng/mL)抑制TNF诱导的uPA合成与分泌的能力。使用uPA和纤溶酶原激活剂抑制剂1型(PAI-1)特异性单克隆抗体(MoAb),通过微酶联免疫吸附测定(ELISA)方法对来自γ-IFN处理培养物的无细胞条件培养基进行分析,结果表明,通过十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)酶谱法观察到的uPA活性降低是细胞外uPA抗原减少的直接结果,而非PAI-1抗原增加的结果。Northern印迹分析支持了这些发现,该分析表明,γ-IFN处理内皮细胞导致uPA信使核糖核酸(mRNA)的稳态水平降低,而PAI-1 mRNA没有可测量的变化。这种抑制反应对γ-IFN具有特异性,因为α-IFN未能引发类似的抑制反应。此外,TNF以剂量依赖性方式增强了放射性标记的内皮下细胞外基质(ECM)的细胞外蛋白水解作用。观察到的TNF处理内皮细胞介导的ECM降解增加依赖于纤溶酶原的存在,并且可被抗催化uPA MoAb抑制,这意味着在此过程中需要具有蛋白水解活性的uPA。γ-IFN(25 ng/mL)处理内皮细胞以完全抑制TNF介导的uPA表达和活性的浓度拮抗TNF促进的放射性标记ECM降解。此外,用TNF(18小时)处理的内皮细胞表现出侵入ECM并将单个细胞重组为管状结构的能力,当在基质胶包被培养皿上生长时,在未处理的对照培养物中不明显。观察到在基质胶上培养的内皮细胞经γ-IFN处理后,在与抑制uPA表达和活性所需浓度相似的浓度下,可抑制TNF介导的ECM侵袭和管形成。总之,这些观察结果提示了一种新的稳态控制机制,用于内皮细胞对由TNF促进并被γ-IFN抑制的内皮下ECM降解的调节。(摘要截短至400字)